Daniel J. Starks - 24 Apr 2026 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Reporting relationship: Director
Issuer ticker: ABT
Reported as of: 24 Apr 2026
Net transaction value: +$926,537
SEC form: 4
Accepted by SEC: 28 Apr 2026, 19:37:56 UTC
Prior SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel J. Starks by Jessica H. Paik, Attorney-in-Fact

Key filing fact

Daniel J. Starks filed Form 4 for ABBOTT LABORATORIES (ABT) on 28 Apr 2026.

Key facts

This page summarizes Daniel J. Starks's Form 4 filing for ABBOTT LABORATORIES (ABT).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Apr 2026, 19:37.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: +$926,537.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000902132 Primary reporting owner

STARKS DANIEL J

Relationship: Director
Address: 100 ABBOTT PARK ROAD, ABBOTT PARK
Signature: /s/ Daniel J. Starks by Jessica H. Paik, Attorney-in-Fact
Signature date: 28 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABT transaction

Common shares without par value

Award

Transaction value
Shares: +2,286
Change %: +0.03%
Price: $0.000000^*
Shares after: 6,741,103
Date: 24 Apr 2026
Ownership: Direct
Footnotes: F1

ABT transaction

Common shares without par value

Purchase

Transaction value: $926,537
Shares: +10,000
Change %: +0.15%
Price: $92.65
Shares after: 6,751,103
Date: 27 Apr 2026
Ownership: Direct
Footnotes: F2

ABT holding

Common shares without par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 258
Date: 24 Apr 2026
Ownership: Alynne Starks 2012 Irrevocable Trust
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABT transaction Derivative

Option (right to buy)

Award

Transaction value
Shares: +7,105
Change %
Price: $0.000000^*
Shares after: 7,105
Date: 24 Apr 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 7,105
Exercise price: $91.86
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.43 to $93.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F3

Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.

Footnote F4

Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.